Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 03, 2010 08:00 ET | Source: Marshall Edwards, Inc.

Marshall Edwards' CEO to Present at Needham Healthcare Conference

SYDNEY, AUSTRALIA and SAN DIEGO, CA--(Marketwire - June 3, 2010) - Marshall Edwards, Inc. (NASDAQ: MSHL), an oncology company focused on the clinical development of novel anti-cancer...
March 19, 2009 13:07 ET | Source: Marshall Edwards, Inc.

Biotech Analyst Joins Board of Directors of Marshall Edwards, Inc.

NEW CANAAN, CT and SYDNEY, AUSTRALIA--(Marketwire - March 19, 2009) - Marshall Edwards, Inc. (NASDAQ: MSHL) is pleased to announce the appointment of Leah Cann to the Board of Directors of the...
January 07, 2009 08:10 ET | Source: Marshall Edwards, Inc.

Marshall Edwards, Inc. Granted IND for Triphendiol

NEW CANAAN, CT--(Marketwire - January 7, 2009) - Marshall Edwards, Inc. (NASDAQ: MSHL) today announced that it has been granted an Investigative New Drug (IND) approval by the United States Food and...
December 01, 2008 08:10 ET | Source: Marshall Edwards, Inc.

Marshall Edwards, Inc. Files IND Application for Triphendiol

NEW CANAAN, CT--(Marketwire - December 1, 2008) - Marshall Edwards, Inc. (NASDAQ: MSHL) today announced that it has filed an application with the United States Food and Drug Administration for an...
May 15, 2008 21:00 ET | Source: Marshall Edwards, Inc.

Clinical Phase I Study Report of Marshall Edwards' Compound Triphendiol to Be Reported in ASCO Proceedings

NEW CANAAN, CT--(Marketwire - May 15, 2008) - An abstract submitted to the Annual Meeting of the American Society of Clinical Oncology (ASCO), May 30-June 3, Chicago, Illinois, entitled "Phase Ia...
April 13, 2008 16:00 ET | Source: Marshall Edwards, Inc.

Marshall Edwards, Inc.'s Investigational Drug Triphendiol (NV-196) Demonstrates Potent Activity Against Biliary Cancers

SAN DIEGO, CA--(Marketwire - April 13, 2008) - Pre-clinical studies presented here today at the annual meeting of the American Association for Cancer Research demonstrate that Marshall Edwards,...
March 25, 2008 08:02 ET | Source: Marshall Edwards, Inc.

Data to Be Presented at AACR Reveals That the Marshall Edwards' Compound Triphendiol May Aid in Treatment of Pancreatic Cancer

NEW CANAAN, CT--(Marketwire - March 25, 2008) - The abstract for a "late breaking" presentation at the Annual Meeting of the American Association for Cancer Research, April 12-16, San Diego, Calif.,...
February 19, 2008 07:31 ET | Source: Marshall Edwards, Inc.

Additional Orphan Drug Status Granted for Melanoma for Marshall Edwards' Investigational Anti-Cancer Drug Triphendiol (NV-196)

NEW CANAAN, CT--(Marketwire - February 19, 2008) - Marshall Edwards, Inc., (NASDAQ: MSHL) announced today that triphendiol (previously known as NV-196) has been granted Orphan Drug status by the U.S....